$KYMR News

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon

Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Wolfe Research Upgrades Kymera Therapeutics to Outperform

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript

Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)

Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary

Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript